Phasebio Pharmaceuticals Stock Return On Equity
| PHASQDelisted Stock | USD 0.0003 0.0001 25.00% |
PhaseBio Pharmaceuticals fundamentals help investors to digest information that contributes to PhaseBio Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of PhaseBio Pink Sheet. The fundamental analysis module provides a way to measure PhaseBio Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PhaseBio Pharmaceuticals pink sheet.
PhaseBio |
PhaseBio Pharmaceuticals Company Return On Equity Analysis
PhaseBio Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, PhaseBio Pharmaceuticals has a Return On Equity of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 100.0% lower than that of the firm.
PhaseBio Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PhaseBio Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of PhaseBio Pharmaceuticals could also be used in its relative valuation, which is a method of valuing PhaseBio Pharmaceuticals by comparing valuation metrics of similar companies.PhaseBio Pharmaceuticals is currently under evaluation in return on equity category among its peers.
PhaseBio Fundamentals
| Return On Asset | -1.06 | |||
| Operating Margin | (127.39) % | |||
| Current Valuation | (1.26 M) | |||
| Shares Outstanding | 49.86 M | |||
| Shares Owned By Insiders | 6.72 % | |||
| Shares Owned By Institutions | 25.02 % | |||
| Number Of Shares Shorted | 2.07 M | |||
| Price To Book | 26.18 X | |||
| Price To Sales | 1.58 X | |||
| Revenue | 10.83 M | |||
| Gross Profit | (91.28 M) | |||
| EBITDA | (126.73 M) | |||
| Net Income | (131.07 M) | |||
| Cash And Equivalents | 7.8 M | |||
| Cash Per Share | 0.16 X | |||
| Total Debt | 1.36 M | |||
| Current Ratio | 0.47 X | |||
| Book Value Per Share | (2.35) X | |||
| Cash Flow From Operations | (47.42 M) | |||
| Short Ratio | 1.89 X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 60 | |||
| Beta | 2.52 | |||
| Market Capitalization | 1.05 M | |||
| Total Asset | 60.54 M | |||
| Z Score | -6.6 | |||
| Net Asset | 60.54 M |
About PhaseBio Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PhaseBio Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PhaseBio Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PhaseBio Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with PhaseBio Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if PhaseBio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PhaseBio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to PhaseBio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PhaseBio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PhaseBio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PhaseBio Pharmaceuticals to buy it.
The correlation of PhaseBio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PhaseBio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PhaseBio Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PhaseBio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in PhaseBio Pink Sheet
If you are still planning to invest in PhaseBio Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PhaseBio Pharmaceuticals' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |